Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-30

Astria Therapeutics (ATXS)

Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$6,604,416
Jill Milne total, FY2024
80th
CEO pay percentile vs peers
CEO-to-median pay ratio
Say-on-pay support, latest vote
Companies that benchmark against ATXS
5 companies name ATXS as a compensation peer

Each company listed discloses ATXS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATXS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jill Milne$637,868$0$0$5,637,078$318,934$0$10,536$6,604,416
President and Chief Executive Officer
Christopher Morabito485,920001,789,892194,368010,5362,480,716
Chief Medical Officer
Benjamin Harshbarger461,617001,789,892184,647011,7772,447,933
Chief Legal Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY20232024
Jill Milne$6,604,416$2,955,504+3,648,912
Christopher Morabito2,480,7161,321,586+1,159,130
Benjamin Harshbarger2,447,9331,297,491+1,150,442

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Benjamin HarshbargerOption48,75013.36
Jill MilneOption19,44417.22
Jill MilneOption56,8756.51
Jill MilneOption148,95813.36
Jill MilneOption534,60015.26
Christopher MorabitoOption39,5833.87
Benjamin HarshbargerOption5,55617.22
Benjamin HarshbargerOption4,16412.96
Benjamin HarshbargerOption16,0426.51
Benjamin HarshbargerOption175,00015.26
Christopher MorabitoOption48,75013.36
Christopher MorabitoOption175,00015.26
05

Incentive-plan design — the Compensation Discussion & Analysis

We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our executives to achieve short- and long-term results that are in the best interests of our stockholders and benchmarking data from our peer group companies. We do not target a specific mix of compensation among base salary, bonus or equity incentives.

CEO STI target (% of salary)50%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
202556,434,219

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
2025a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Sunil AgarwalIndependent · Science and Technology$34,973$0$221,309$0$256,282
Kenneth BateIndependent · Board Chair · Audit · Nominating/Governance (Chair)90,500086,9800177,480
Gregg LapointeIndependent · Audit (Chair)60,000086,9800146,980
Jonathan ViolinIndependent · Science and Technology (Chair)55,000086,9800141,980
Michael KishbauchIndependent · Compensation (Chair) · Nominating/Governance54,000086,9800140,980
Joanne BeckIndependent · Compensation · Science and Technology52,500086,9800139,480
Fred CalloriIndependent · Compensation · Nominating/Governance49,000086,9800135,980
Hugh ColeIndependent · Audit · Compensation48,750086,9800135,730
Jill C. MilneEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 10,000 / 8,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$444,723
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$444,723

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

EWTX Edgewise Therapeutics, Inc.RLYB Rallybio Reneo Pharmaceuticals, Inc.LRMR Larimar Therapeutics, Inc.FHTX Foghorn Therapeutics, Inc.THRD Third Harmonic BioOCGN Ocugen, Inc.VRDN Viridian Therapeutics, Inc.SVRA Savara, Inc.ACET Adicet Bio, Inc.INZY Inozyme Pharma, Inc.HOWL Werewolf Therapeutics, Inc.VIGL Vigil Neuroscience, Inc. Aerovate Therapeutics, Inc.ANNX Annexon Biosciences AVROBIO, Inc.CUE Cue Biopharma, Inc.
10a

Peer reciprocity

Of the companies Astria Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Edgewise Therapeutics, Inc. (EWTX) Rallybio (RLYB) Larimar Therapeutics, Inc. (LRMR) Foghorn Therapeutics, Inc. (FHTX) Third Harmonic Bio (THRD) Ocugen, Inc. (OCGN) Viridian Therapeutics, Inc. (VRDN)22 Savara, Inc. (SVRA)23 Adicet Bio, Inc. (ACET) Inozyme Pharma, Inc. (INZY) Werewolf Therapeutics, Inc. (HOWL) Vigil Neuroscience, Inc. (VIGL) Annexon Biosciences (ANNX) Cue Biopharma, Inc. (CUE)

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Astria Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Viridian Therapeutics, Inc.2025Stephen Mahoney$700,000$1,058,098$4,381,713$630,000$6,776,249
2Astria Therapeutics2024Jill Milne637,86805,637,078318,9346,604,416
3Savara, Inc.2025Matthew Pauls660,0003,870,0000297,0004,845,000
4Larimar Therapeutics, Inc.2025Carole Ben-Maimon650,000660,8601,889,16003,526,423
5Inozyme Pharma, Inc.2024Douglas Treco541,66701,933,37502,485,392
6Foghorn Therapeutics, Inc.2025Adrian Gottschalk638,00001,334,037385,9902,361,027
Edgewise Therapeutics, Inc.not in coverage universe
Rallybionot in coverage universe
Third Harmonic Bionot in coverage universe
Ocugen, Inc.not in coverage universe
Adicet Bio, Inc.not in coverage universe
Werewolf Therapeutics, Inc.not in coverage universe
Vigil Neuroscience, Inc.not in coverage universe
Annexon Biosciencesnot in coverage universe
Cue Biopharma, Inc.not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Astria Therapeuticsnot disclosedOptions 100not disclosedAon
Adicet Bio, Inc.not disclosednot disclosednot disclosednot disclosed
Annexon Biosciencesnot disclosednot disclosednot disclosednot disclosed
Cue Biopharma, Inc.not disclosednot disclosednot disclosednot disclosed
Edgewise Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Foghorn Therapeutics, Inc.not disclosedOptions 100not disclosedPay Governance, LLC
Inozyme Pharma, Inc.not disclosednot disclosednot disclosedAlpine Rewards
Larimar Therapeutics, Inc.86%Options 75 · RSU 25NoAon
Ocugen, Inc.not disclosednot disclosednot disclosednot disclosed
Rallybionot disclosednot disclosednot disclosednot disclosed
Savara, Inc.90%RSU 100not disclosedAon
Third Harmonic Bionot disclosednot disclosednot disclosednot disclosed
Vigil Neuroscience, Inc.not disclosednot disclosednot disclosednot disclosed
Viridian Therapeutics, Inc.150%Options 75 · RSU 25not disclosedCompensia
Werewolf Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jill MilneDEF 14A2025-04-280001104659-25-040180Section “Summary Compensation Table”. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460
2Section 01, Christopher MorabitoDEF 14A2025-04-280001104659-25-040180Section “Summary Compensation Table”. As printed: 2,480,716. Filing ↗machine: r3 · c35 · span 334778–334787
3Section 01, Benjamin HarshbargerDEF 14A2025-04-280001104659-25-040180Section “Summary Compensation Table”. As printed: 2,447,933. Filing ↗machine: r5 · c35 · span 342095–342104
4Section 08, Sunil AgarwalDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 256,282. Filing ↗machine: t7 · r1 · c23 · span 240649–240656
5Section 08, Kenneth BateDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 177,480. Filing ↗machine: t7 · r2 · c23 · span 243228–243235
6Section 08, Gregg LapointeDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 146,980. Filing ↗machine: t7 · r7 · c23 · span 256201–256208
7Section 08, Jonathan ViolinDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 141,980. Filing ↗machine: t7 · r8 · c23 · span 258783–258790
8Section 08, Michael KishbauchDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 140,980. Filing ↗machine: t7 · r6 · c23 · span 253595–253602
9Section 08, Joanne BeckDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 139,480. Filing ↗machine: t7 · r3 · c23 · span 245831–245838
10Section 08, Fred CalloriDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 135,980. Filing ↗machine: t7 · r4 · c23 · span 248410–248417
11Section 08, Hugh ColeDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 135,730. Filing ↗machine: t7 · r5 · c23 · span 251011–251018
12Section 08, Jill C. MilneDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 0. Filing ↗
13Section 06, 2025 voteForm 8-K2025-04-280001104659-25-040180Item 5.07 · say-on-pay result. As reported: —. Filing ↗
14Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
15Section 09b board cost (computed)ComputedcomputedCash 444,723 + equity 0 + all other 0 = 444,723, summed across the director compensation table rows.machine: formula: Σ = 444,723
16Viridian Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-170001193125-26-160344CEO total compensation as printed in Viridian Therapeutics, Inc.'s own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778
17Astria Therapeutics (subject), Section 10b CEO totalDEF 14A2025-04-280001104659-25-040180CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460
18Savara, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177353CEO total compensation as printed in Savara, Inc.'s own proxy. As printed: 4,845,000. Filing ↗machine: r2 · c30 · span 340387–340396
19Larimar Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001193125-26-163942CEO total compensation as printed in Larimar Therapeutics, Inc.'s own proxy. As printed: 3,526,423. Filing ↗machine: t90 · r3 · c39 · span 812416–812425
20Inozyme Pharma, Inc., Section 10b CEO totalDEF 14A2025-04-290000950170-25-060198CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355
21Foghorn Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-193928CEO total compensation as printed in Foghorn Therapeutics, Inc.'s own proxy. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369
22Section 10a, Viridian Therapeutics, Inc. reciprocityDEF 14A0001193125-26-160344Viridian Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Astria Therapeutics. Filing ↗
23Section 10a, Savara, Inc. reciprocityDEF 14A0001193125-26-177353Savara, Inc. names Astria Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗